Trial Profile

An Investigator-initiated Clinical Study Evaluating the CRISPR-hfCas12Max Gene Editing Therapy in the Treatment of Duchenne Muscular Dystrophy (DMD)

Status: Active, no longer recruiting

Phase of Trial: Phase 0

Latest Information Update: 06 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HG 302 (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions
Acronyms MUSCLE
Sponsors HuidaGene Therapeutics

Most Recent Events

03 Aug 2026 Planned End Date changed from 30 Sep 2026 to 2 Jun 2027.
03 Aug 2026 Planned primary completion date changed from 30 Sep 2026 to 2 Aug 2026.
03 Aug 2026 Status changed from completed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com